| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/30/2007 | US20070202191 Bone graft materials derived from mineralized gelatin |
| 08/30/2007 | US20070202190 extracting gelatin solution from bone with acid, while retaining minerals in gelatin solution; kits |
| 08/30/2007 | US20070202186 Apparatus and formulations for suprachoroidal drug delivery |
| 08/30/2007 | US20070202178 Drug delivery matrices to enhance wound healing |
| 08/30/2007 | US20070202157 Delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome |
| 08/30/2007 | US20070202153 Liquid Concentrated Formula |
| 08/30/2007 | US20070202147 Poly(ester amide)-based drug delivery systems with controlled release rate and morphology |
| 08/30/2007 | US20070202145 Method for incorporation of bioactives into a porous hydrophobic polymer scaffold |
| 08/30/2007 | US20070202132 Allergenic proteins and peptides from dog dander and uses therefor |
| 08/30/2007 | US20070202129 Use of the neurotoxic component of a botulinum toxin for the treatment of pain associated with muscle activity or contracture |
| 08/30/2007 | US20070202127 comprise DP178 peptide corresponding to amino acids 638 to 673 of the HIV-1LAI gp41 protein; inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells |
| 08/30/2007 | US20070202125 Inhibiting rejection of a graft |
| 08/30/2007 | US20070202124 Method for the production of purified invasin protein and use thereof |
| 08/30/2007 | US20070202123 Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids |
| 08/30/2007 | US20070202122 Non-splicing variants of gp350/220 |
| 08/30/2007 | US20070202121 SPAS-1 cancer antigen |
| 08/30/2007 | US20070202120 Yellow Fever Mosquito Deoxyribonucleoside Kinases And Its Use |
| 08/30/2007 | US20070202116 Staphylococcal infections using glycopeptide antibiotic eg vancomycin |
| 08/30/2007 | US20070202115 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 08/30/2007 | US20070202110 Angiogenesis Inhibiting Molecules And Their Use In The Treatment And Diagnosis Of Cancer |
| 08/30/2007 | US20070202107 Novel kinases |
| 08/30/2007 | US20070202101 Combination therapy using anti-EGFR antibodies and anti-hormonal agents |
| 08/30/2007 | US20070202100 Using programmed death-1 (PD-1) protein as evaluative tool to identify modulators for treatment and prevention of nervous system, autoimmune, cell proliferative and allergic disorders |
| 08/30/2007 | US20070202096 XAF genes and polypeptides: methods and reagents for modulating apoptosis |
| 08/30/2007 | US20070202094 TIMP3 as VEGF inhibitor |
| 08/30/2007 | US20070202093 Systems and Methods to Reduce Gel Retraction |
| 08/30/2007 | US20070202092 Use of beta-1,3 (4)-endoglucanohydrolase beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| 08/30/2007 | US20070202091 Nutraceutical composition and method for promoting the rejuvenation of cells in warm-blooded animals including humans |
| 08/30/2007 | US20070202090 Water Soluble Form Of Coenzyme Q10 In The Form Of An Inclusion Complex With Beta-Cyclodextrin, Process Of Preparing, And Use Thereof |
| 08/30/2007 | US20070202079 Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases |
| 08/30/2007 | US20070202078 Method Of Treating Viral Infections |
| 08/30/2007 | US20070202077 Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders |
| 08/30/2007 | US20070202075 Tissue adhesives and sealants and method for their use |
| 08/30/2007 | US20070202051 Aerosols for sinunasal drug delivery |
| 08/30/2007 | US20070202045 Serum albumin binding peptides for tumor targeting |
| 08/30/2007 | US20070202044 Antibody therapy |
| 08/30/2007 | US20070202043 Cell surface glycoprotein specific immunoglobulin for use in prevention and treatment of cell proliferative disorders; antitumor agents |
| 08/30/2007 | US20070202042 Isolated monoclonal antibody produced by hybridoma deposit IDAC accession number 141205-02; customization of therapy for each individual; kits |
| 08/30/2007 | US20070202041 Cancerous disease modifying antibodies |
| 08/30/2007 | DE60122300T2 Hepatitis b kernprotein fusionsproteine Hepatitis B core protein fusion proteins |
| 08/30/2007 | DE102006008613A1 Stabilisierte Zubereitungen von Serin-Endopeptidasen, deren Herstellung und Verwendung Stabilized preparations of serine endopeptidases, their preparation and use |
| 08/30/2007 | DE102004055891B4 Gemische von Schlangengiften zur Krankheitsbekämpfung Mixtures of snake venoms disease control |
| 08/30/2007 | CA2651793A1 Hiv fusion inhibitor peptides with improved biological properties |
| 08/30/2007 | CA2643561A1 Cancerous disease modifying antibody 141205-05 |
| 08/30/2007 | CA2643464A1 A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| 08/30/2007 | CA2643130A1 Compounds and methods of treating disorders associated with activation of metachromatic cells |
| 08/30/2007 | CA2643063A1 Cancerous disease modifying antibody 141205-02 |
| 08/30/2007 | CA2643048A1 Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor |
| 08/30/2007 | CA2642910A1 Coagulation factor x polypeptides with modified activation properties |
| 08/30/2007 | CA2642264A1 Reca inhibitors with antibiotic activity, compositions and methods of use |
| 08/30/2007 | CA2641909A1 Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition |
| 08/30/2007 | CA2641908A1 Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| 08/30/2007 | CA2638828A1 Immunomodulatory and anti-tumor peptides derived from lalf |
| 08/30/2007 | CA2638827A1 Protection of the retina against laser injury by adnf peptides such as nap and sal |
| 08/30/2007 | CA2638775A1 Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody |
| 08/30/2007 | CA2638122A1 Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same |
| 08/30/2007 | CA2638065A1 Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes |
| 08/30/2007 | CA2636449A1 Vascular tumor markers |
| 08/30/2007 | CA2635472A1 Soluble receptors and methods for treating autoimmune or demyelinating diseases |
| 08/30/2007 | CA2634473A1 Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
| 08/29/2007 | EP1826217A1 Method for identification of antigenic peptides |
| 08/29/2007 | EP1826216A1 Glp-1 derivatives |
| 08/29/2007 | EP1826215A2 Method of obtaining the expression or improving the rate of expression of a gene |
| 08/29/2007 | EP1825865A2 Stabilised preparations of serine endopeptidases, their production and application |
| 08/29/2007 | EP1825864A2 Antithrombotic agents |
| 08/29/2007 | EP1825862A1 Method for treating nerve injury and vector construct for the same |
| 08/29/2007 | EP1824979A2 Methods, products and uses involving platelets and/or the vasculature |
| 08/29/2007 | EP1824976A1 Antimicrobial peptides |
| 08/29/2007 | EP1824969A1 Improved mevalonate kinase |
| 08/29/2007 | EP1824882A1 Osteoprotegerin variant proteins |
| 08/29/2007 | EP1824881A1 Tgr3-like protein receptor |
| 08/29/2007 | EP1824878A1 Tnf antagonists |
| 08/29/2007 | EP1824876A2 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 08/29/2007 | EP1824874A1 Pure vancomycin hydrochloride |
| 08/29/2007 | EP1824873A1 Use of derivatives of dipeptides for the manufacture of a medicament for the treatment of microbial infections |
| 08/29/2007 | EP1824775A2 Debriding composition from bromelain and methods of production thereof |
| 08/29/2007 | EP1824519A2 Inhibition of li expression in mammalian cells |
| 08/29/2007 | EP1824514A2 Toll like receptor 3 antagonists, methods and uses |
| 08/29/2007 | EP1824510A2 Use of flagellin in the immunotherapy of yersinia pestis |
| 08/29/2007 | EP1824508A1 T-cell modulation |
| 08/29/2007 | EP1824507A1 Treatment of hepatitis c in the asian population with interferon-beta |
| 08/29/2007 | EP1824506A2 Use of organic compounds |
| 08/29/2007 | EP1824505A1 Method for determining inflammatory processes, and pharmaceutical compositions for the treatment thereof |
| 08/29/2007 | EP1824504A1 Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivatives |
| 08/29/2007 | EP1824503A1 Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
| 08/29/2007 | EP1824501A1 Protein hydrolysate with antidiabetic effect |
| 08/29/2007 | EP1824499A2 Compositions for treatment of ear infections |
| 08/29/2007 | EP1824498A2 Methods and compositions for treating cellular proliferative diseases |
| 08/29/2007 | EP1670903B1 Treatment of neurodegenerative diseases |
| 08/29/2007 | EP1572952A4 Novel polynucleotide and polypeptide sequences and uses thereof |
| 08/29/2007 | EP1562629A4 Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
| 08/29/2007 | EP1490091B1 Enhancement of endogenous gonadotropin production |
| 08/29/2007 | EP1485138A4 Medical device for delivering biologically active material |
| 08/29/2007 | EP1465654A4 Plasmid mediated suplementation for treating chronically ill subjects |
| 08/29/2007 | EP1450847A4 Apo2 ligand/trail formulations |
| 08/29/2007 | EP1450813B1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of menorrhagia |
| 08/29/2007 | EP1414961B1 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 08/29/2007 | EP1333840B9 M. tuberculosis chaperonin 60.1 and uses thereof |
| 08/29/2007 | EP1280889B1 Compositions and methods for producing antigen-presenting cells |
| 08/29/2007 | EP1259120B1 Method for isolating collagen from marine sponge and producing nanoparticulate collagen, and the use thereof |